Gohji K, Nomi M, Egawa S, Morisue K, Takenaka A, Okamoto M, Ohori M, Fujii A
Department of Urology, Hyogo Medical Center for Adults, Akashi, Japan.
Cancer. 1997 May 15;79(10):1969-76. doi: 10.1002/(sici)1097-0142(19970515)79:10<1969::aid-cncr19>3.0.co;2-t.
This study was undertaken to determine whether the prostate specific antigen (PSA) density (PSAD) and PSAD of the transition zone (PSADT) are useful in the detection of prostate carcinoma in Japanese men with intermediate levels of serum PSA.
Two hundred and eighty-seven Japanese men with intermediate serum PSA levels (2.1 ng/mL to 10 ng/mL) underwent measurement of prostate volume by transrectal ultrasound (TRUS) and systematic biopsy under TRUS guidance. The volume of the transition zone was also measured by TRUS in 134 patients. The PSAD and PSADT were determined for each patient, and their relationship to prostate carcinoma detection was examined.
Prostate carcinoma was detected in 30 of 287 patients (10.5%). Although the serum PSA levels were similar in patients with benign and malignant prostate disease (P = 0.541), the prostate volume (P 0.0009) and PSAD (P < 0.0001) differed significantly in the two groups; in the patients with prostate carcinoma, the prostate volume was smaller, and the PSAD higher, than in the patients with benign disease. At the PSAD cutoff value of 0.18 ng/mL/cm3 or greater, the sensitivity was 70% and the specificity was 67% for the diagnosis of prostate carcinoma. The PSAD was found to be significantly better in the differentiation between benign and malignant prostate disease than the serum PSA in the receiver operating characteristic analyses (P = 0.045). However, the receiver operating characteristic curve for PSAD was not significantly different compared with that for PSA in the men with negative digital rectal examination findings. Prostate carcinoma was detected in 9.0% (12 of 134) of the patients who underwent PSADT determination. Receiver operating characteristic analyses showed that PSADT was not superior to PSA in the detection of prostate carcinoma.
In Japanese men with intermediate serum PSA concentrations, PSAD offers additional information useful in the detection of prostate carcinoma, but PSADT does not. Although use of PSAD may decrease the number of unnecessary biopsies, a significant number of prostate carcinomas may be overlooked. Therefore, the authors recommend that serum PSA levels continue to be used as an indicator for biopsy in Japanese men.
本研究旨在确定前列腺特异性抗原(PSA)密度(PSAD)及移行区PSAD(PSADT)在检测血清PSA水平处于中等范围的日本男性前列腺癌时是否有用。
287名血清PSA水平中等(2.1 ng/mL至10 ng/mL)的日本男性接受经直肠超声(TRUS)测量前列腺体积,并在TRUS引导下进行系统活检。134名患者还通过TRUS测量了移行区体积。计算每名患者的PSAD和PSADT,并检查它们与前列腺癌检测的关系。
287名患者中有30名(10.5%)检测出前列腺癌。虽然前列腺良性和恶性疾病患者的血清PSA水平相似(P = 0.541),但两组患者的前列腺体积(P = 0.0009)和PSAD(P < 0.0001)差异显著;前列腺癌患者的前列腺体积比良性疾病患者小,PSAD更高。当PSAD临界值为0.18 ng/mL/cm³或更高时,诊断前列腺癌的敏感性为70%,特异性为67%。在接受者操作特征分析中,发现PSAD在区分前列腺良性和恶性疾病方面明显优于血清PSA(P = 0.045)。然而,在直肠指检结果为阴性的男性中,PSAD的接受者操作特征曲线与PSA的曲线相比无显著差异。进行PSADT测定的患者中有9.0%(134名中的12名)检测出前列腺癌。接受者操作特征分析表明,PSADT在检测前列腺癌方面并不优于PSA。
在血清PSA浓度中等的日本男性中,PSAD为前列腺癌检测提供了额外有用信息,但PSADT并非如此。虽然使用PSAD可能会减少不必要活检的数量,但仍可能有大量前列腺癌被漏诊。因此,作者建议血清PSA水平继续作为日本男性活检的指标。